
Lyell Immunopharma (LYEL) Stock Forecast & Price Target
Lyell Immunopharma (LYEL) Analyst Ratings
Bulls say
Lyell Immunopharma, Inc. reported a strong financial position with cash, cash equivalents, and marketable securities increasing to $320 million as of the end of the latest quarter, up from $297 million in the previous quarter, primarily due to a successful private placement. The company is making significant advancements in its pipeline, particularly with the dual-targeting CAR T-cell therapy, rondecabtagene autoleucel, which has established a best-in-class profile, as well as potential opportunities with a novel CAR T-cell candidate for refractory metastatic colorectal cancer. Expert feedback suggests Lyell's existing dataset for LYL273 has surpassed clinical expectations for success in treating advanced colorectal cancer, further strengthening the company's growth prospects in the CAR T-cell therapy market.
Bears say
Lyell Immunopharma experienced a decline in research and development expenses to $28.2 million in the third quarter of 2025, down from $34.9 million in the previous quarter, signifying potential financial constraints in advancing its pipeline. The company faces significant risks, including challenges in growing the CAR-T market for non-Hodgkin lymphoma, potential deterioration in the efficacy of its product candidates, and possible safety concerns that could adversely affect their marketability. Concerns regarding the durability of treatment responses and the management of toxicities further hamper the company's outlook, as existing data does not provide sufficient assurance of its products' effectiveness and safety at scale.
This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.
Lyell Immunopharma (LYEL) Analyst Forecast & Price Prediction
Start investing in Lyell Immunopharma (LYEL)
Order type
Buy in
Order amount
Est. shares
0 shares